A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

ABSTRACT:

Background

Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumour cells. A phase Ib trial of P plus chemotherapy was undertaken to evaluate the safety and efficacy.

Methods

Patients with advanced, metastatic solid tumours were enrolled onto one of six treatment arms. Pembrolizumab was given: with gemcitabine (G), G+docetaxel (D), G+nab-paclitaxel (NP), G+vinorelbine (V) or irinotecan (I) until progression or toxicity, or with liposomal doxorubicin (LD) for up to 15 cycles, progression or toxicity. Safety monitoring and response assessments were conducted.

Results

Forty-nine patients were enrolled and treated. The most common adverse events were transaminitis, cytope

SUBMITTER: Weiss GJ 

PROVIDER: S-EPMC5520208 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature